Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 0.72 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.45 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CMA1 | P23946 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28868430 | 0.88 | ROCK2 (0.56) | ROCK2TP53ADORA3PIK3R1PIK3CA | |
| SCHEMBL19643674 | 0.88 | ROCK2 (0.56) | ROCK2TP53ADORA3PIK3R1PIK3CA | |
| SCHEMBL19643570 | 0.88 | ROCK2 (0.58) | ROCK2TP53ADORA3PIK3R1PIK3CA | |
| SCHEMBL19643173 | 0.84 | ROCK2 (1.00) | ROCK2 | |
| SCHEMBL19643781 | 0.84 | ROCK2 (0.67) | ROCK2TP53PIK3R1PIK3CAMAPT | |
| SCHEMBL19644451 | 0.82 | ROCK2 (0.51) | ROCK2TP53ADORA3PIK3R1PIK3CA | |
| SCHEMBL21024665 | 0.80 | ROCK2 (0.59) | ROCK2TP53ADORA3MAPT | |
| SCHEMBL19643227 | 0.79 | ROCK2 (0.50) | ROCK2TP53PIK3R1PIK3CAMAPT | |
| SCHEMBL19643602 | 0.75 | ROCK2 (0.60) | ROCK2TP53PIK3R1PIK3CAMAPT | |
| SCHEMBL19643876 | 0.72 | ROCK2 (0.84) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109153663-B | Triazolones and tetrazolones as ROCK inhibitors | 百时美施贵宝公司 | 2021-08-13 | — | — | CN | disclosed |
| EP-3464262-B1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-3464262-B1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-02-26 | — | — | EP | disclosed |
| US-10562887-B2 | Triazolones and tetrazolones as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562887-B2 | Triazolones and tetrazolones as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190152956-A1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-05-23 | — | — | US | disclosed |
| US-20190152956-A1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-05-23 | — | — | US | disclosed |
| EP-3464262-A1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017205709-A1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017205709-A1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152956-A1 | TRIAZOLONES AND TETRAZOLONES AS INHIBITORS OF ROCK | MYLK, ROCK1, MYLK2 | ROCK2 5/4885TP53 2634/4885ADORA3 2989/4885 |
| US-10562887-B2 | Triazolones and tetrazolones as inhibitors of ROCK | MYLK, ROCK1, MYLK2 | ROCK2 5/4885TP53 2634/4885ADORA3 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.